In October 2011, GT Life Sciences Inc was acquired by Intrexon Corporation. GT Life Sciences (GT) is a privately-held biotechnology company formed to pursue the life science applications of the integrated metabolic engineering platform developed by Genomatica Inc. GT utilizes a validated platform encompassing predictive models of metabolism and experimental technologies to accelerate biological research and discovery. Now utilizing this powerful new paradigm, the company is advancing the frontiers of biological discovery and development for both GT and its partners. GT owns a large collection of in silico models which include tissue-specific human metabolism, mammalian cell lines, microbial cells, and key pathogens. GT owns and has licenses to over 80 patent/patent applications.
